Docetaxel vs Cabazitaxel for Prostate Cancer
(CABPOSTAAT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests if cabazitaxel plus prednisone can help patients with advanced prostate cancer that hasn't responded to other treatments. Cabazitaxel stops cancer cells from growing, and prednisone helps manage side effects. Cabazitaxel was approved by the US FDA after a previous study showed improved survival in patients who had previously been treated with another medication.
Who Is on the Research Team?
fred Saad, MD
Principal Investigator
CHUM
Are You a Good Fit for This Trial?
Men with advanced prostate cancer that has spread and worsened despite hormone therapy with abiraterone or enzalutamide. They must have a rising PSA level, measurable disease progression, effective castration (low testosterone), and be able to consent. Excluded are those who've had certain prior treatments, uncontrolled other cancers or medical conditions, severe side effects from past cancer therapies, or inadequate organ function.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either cabazitaxel plus prednisone or docetaxel plus prednisone until disease progression, unacceptable toxicity, or refusal of further treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- Cabazitaxel
- Docetaxel
Cabazitaxel is already approved in European Union, United States, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor
Genzyme, a Sanofi Company
Industry Sponsor
David Meeker
Genzyme, a Sanofi Company
Chief Executive Officer since 2011
MD from the University of Vermont Medical School, Advanced Management Program at Harvard Business School
Jean-Paul Kress
Genzyme, a Sanofi Company
Chief Medical Officer since 2015
MD from Faculte Necker-Enfants Malades, Paris